Albireo Pharma 2017 BIO CEO Investor Conference Presentation

Albireo Pharma presents its portfolio of bile acid modulators for orphan pediatric liver diseases at the BIO CEO & Investor Conference. The company highlights its lead candidate A4250 in development for Progressive Familial Intrahepatic Cholestasis (PFIC) and chronic cholestasis, along with partnered asset elobixibat.